Eleanor Elizabeth Russell-Goldman, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sweat Gland Neoplasms | 4 | 2022 | 108 | 2.820 |
Why?
|
| Hair Diseases | 3 | 2023 | 74 | 1.840 |
Why?
|
| Skin Neoplasms | 13 | 2023 | 5686 | 1.830 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2023 | 545 | 1.650 |
Why?
|
| Hamartoma Syndrome, Multiple | 2 | 2023 | 111 | 1.610 |
Why?
|
| Muir-Torre Syndrome | 1 | 2023 | 13 | 0.950 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2023 | 21 | 0.940 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2023 | 39 | 0.920 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2023 | 109 | 0.870 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2022 | 18 | 0.870 |
Why?
|
| Acrospiroma | 1 | 2022 | 13 | 0.860 |
Why?
|
| Immunohistochemistry | 6 | 2023 | 11366 | 0.840 |
Why?
|
| Mucin-2 | 1 | 2022 | 49 | 0.840 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2023 | 4034 | 0.830 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2022 | 88 | 0.820 |
Why?
|
| Fibroma | 1 | 2023 | 212 | 0.820 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2021 | 66 | 0.780 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2023 | 224 | 0.780 |
Why?
|
| Nevus | 1 | 2023 | 204 | 0.770 |
Why?
|
| Eccrine Porocarcinoma | 1 | 2020 | 15 | 0.770 |
Why?
|
| Neoplasms, Fibroepithelial | 1 | 2020 | 8 | 0.760 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2020 | 75 | 0.690 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2022 | 198 | 0.690 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2020 | 58 | 0.680 |
Why?
|
| Precancerous Conditions | 2 | 2023 | 975 | 0.670 |
Why?
|
| Skin Aging | 1 | 2020 | 127 | 0.660 |
Why?
|
| Antibodies, Antinuclear | 1 | 2020 | 326 | 0.650 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 931 | 0.570 |
Why?
|
| Nuclear Proteins | 5 | 2022 | 5853 | 0.540 |
Why?
|
| Hodgkin Disease | 1 | 2023 | 1415 | 0.520 |
Why?
|
| Neuroblastoma | 1 | 2022 | 1226 | 0.490 |
Why?
|
| Repressor Proteins | 2 | 2022 | 3023 | 0.460 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 1094 | 0.460 |
Why?
|
| Klebsiella Infections | 1 | 2013 | 138 | 0.420 |
Why?
|
| Zebrafish Proteins | 1 | 2018 | 1005 | 0.420 |
Why?
|
| Melanoma | 4 | 2023 | 5510 | 0.400 |
Why?
|
| Klebsiella pneumoniae | 1 | 2013 | 251 | 0.400 |
Why?
|
| beta-Lactamases | 1 | 2013 | 306 | 0.400 |
Why?
|
| Sarcoma | 1 | 2022 | 1897 | 0.380 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 2916 | 0.360 |
Why?
|
| Mutation | 8 | 2023 | 29786 | 0.350 |
Why?
|
| Escherichia coli Infections | 1 | 2013 | 532 | 0.350 |
Why?
|
| Piperazines | 1 | 2020 | 2488 | 0.340 |
Why?
|
| Transcription Factors | 4 | 2022 | 12208 | 0.340 |
Why?
|
| Homeodomain Proteins | 1 | 2018 | 2421 | 0.340 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3703 | 0.320 |
Why?
|
| Pyridines | 1 | 2020 | 2825 | 0.310 |
Why?
|
| Gene Rearrangement | 2 | 2023 | 1179 | 0.300 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2023 | 1142 | 0.280 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 9648 | 0.280 |
Why?
|
| Lung Neoplasms | 3 | 2019 | 13102 | 0.260 |
Why?
|
| Cross Infection | 1 | 2013 | 1416 | 0.240 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 5221 | 0.220 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2023 | 188 | 0.220 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2023 | 75 | 0.220 |
Why?
|
| Nevus, Blue | 1 | 2022 | 38 | 0.210 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2023 | 188 | 0.210 |
Why?
|
| Humans | 32 | 2023 | 744343 | 0.200 |
Why?
|
| Trans-Activators | 2 | 2022 | 2924 | 0.200 |
Why?
|
| Eczema | 1 | 2023 | 231 | 0.200 |
Why?
|
| Escherichia coli | 1 | 2013 | 4217 | 0.190 |
Why?
|
| Drug Eruptions | 1 | 2023 | 297 | 0.190 |
Why?
|
| Facial Transplantation | 1 | 2023 | 226 | 0.180 |
Why?
|
| Gene Fusion | 1 | 2023 | 371 | 0.180 |
Why?
|
| Uveal Neoplasms | 1 | 2022 | 310 | 0.180 |
Why?
|
| Scalp | 1 | 2022 | 380 | 0.180 |
Why?
|
| Hair Follicle | 1 | 2021 | 209 | 0.170 |
Why?
|
| Exanthema | 1 | 2023 | 501 | 0.170 |
Why?
|
| Sarcoma, Small Cell | 1 | 2018 | 22 | 0.170 |
Why?
|
| beta Catenin | 1 | 2023 | 1059 | 0.150 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2008 | 1832 | 0.150 |
Why?
|
| Receptors, Androgen | 1 | 2023 | 1058 | 0.150 |
Why?
|
| DNA Helicases | 1 | 2022 | 859 | 0.150 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13695 | 0.140 |
Why?
|
| Dermatomyositis | 1 | 2019 | 224 | 0.140 |
Why?
|
| Translocation, Genetic | 1 | 2022 | 1420 | 0.140 |
Why?
|
| Central Nervous System Cysts | 1 | 2016 | 58 | 0.140 |
Why?
|
| Retrospective Studies | 7 | 2023 | 77449 | 0.140 |
Why?
|
| Carcinoma, Small Cell | 1 | 2018 | 420 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2008 | 2958 | 0.140 |
Why?
|
| Diagnosis, Differential | 3 | 2022 | 12959 | 0.140 |
Why?
|
| Dermoid Cyst | 1 | 2016 | 93 | 0.140 |
Why?
|
| Antigens, Neoplasm | 1 | 2023 | 1988 | 0.130 |
Why?
|
| Psoriasis | 1 | 2023 | 898 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2008 | 1912 | 0.130 |
Why?
|
| Leg Ulcer | 1 | 2015 | 69 | 0.130 |
Why?
|
| Bacterial Proteins | 1 | 2008 | 3848 | 0.120 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2018 | 300 | 0.120 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 1581 | 0.120 |
Why?
|
| Aged | 8 | 2023 | 163280 | 0.120 |
Why?
|
| Thrombin | 1 | 2016 | 598 | 0.120 |
Why?
|
| Craniopharyngioma | 1 | 2016 | 281 | 0.120 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2013 | 143 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 1813 | 0.110 |
Why?
|
| Cytokines | 1 | 2008 | 7322 | 0.110 |
Why?
|
| Molecular Typing | 1 | 2013 | 106 | 0.110 |
Why?
|
| Exons | 1 | 2019 | 2437 | 0.110 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 594 | 0.110 |
Why?
|
| Female | 13 | 2023 | 380194 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 1101 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 4186 | 0.100 |
Why?
|
| Observer Variation | 1 | 2018 | 2593 | 0.100 |
Why?
|
| Biopsy | 1 | 2023 | 6756 | 0.100 |
Why?
|
| Molecular Epidemiology | 1 | 2013 | 468 | 0.100 |
Why?
|
| Protozoan Proteins | 1 | 2016 | 827 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 4851 | 0.090 |
Why?
|
| Male | 10 | 2023 | 350118 | 0.090 |
Why?
|
| Middle Aged | 7 | 2023 | 213383 | 0.090 |
Why?
|
| Skin | 1 | 2023 | 4364 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2016 | 3144 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2022 | 4456 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 57776 | 0.090 |
Why?
|
| Adult | 6 | 2023 | 214055 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3597 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 1179 | 0.080 |
Why?
|
| Germ-Free Life | 1 | 2008 | 188 | 0.080 |
Why?
|
| Pituitary Neoplasms | 1 | 2016 | 1345 | 0.080 |
Why?
|
| Blotting, Southern | 1 | 2008 | 803 | 0.080 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 1477 | 0.080 |
Why?
|
| Genetic Complementation Test | 1 | 2008 | 562 | 0.080 |
Why?
|
| Plasmodium falciparum | 1 | 2016 | 1732 | 0.070 |
Why?
|
| Prognosis | 2 | 2023 | 29063 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 4253 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 14722 | 0.060 |
Why?
|
| DNA, Bacterial | 1 | 2008 | 1465 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 20822 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2022 | 100 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2023 | 315 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 19905 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2008 | 2751 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2022 | 657 | 0.050 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2022 | 252 | 0.040 |
Why?
|
| Necrosis | 1 | 2023 | 1643 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2022 | 1185 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2008 | 3200 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2016 | 19229 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2649 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 4420 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2020 | 547 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2023 | 3616 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2008 | 10252 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2020 | 1641 | 0.030 |
Why?
|
| Neoplasms | 1 | 2023 | 21683 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1788 | 0.030 |
Why?
|
| Macrophages | 1 | 2008 | 5655 | 0.030 |
Why?
|
| Animals | 2 | 2020 | 168757 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2008 | 14557 | 0.030 |
Why?
|
| Graft Survival | 1 | 2023 | 3737 | 0.030 |
Why?
|
| Leg | 1 | 2015 | 1116 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 21827 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2023 | 4397 | 0.020 |
Why?
|
| Proteomics | 1 | 2023 | 3638 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 11031 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2016 | 2455 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 9274 | 0.020 |
Why?
|
| Phenotype | 1 | 2023 | 16365 | 0.020 |
Why?
|
| Young Adult | 2 | 2023 | 56430 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2016 | 3479 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 81183 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2023 | 40561 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2015 | 9146 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 17446 | 0.010 |
Why?
|